| MDS diagnosis |
| FITC |
CD14 (30x) MoP9 (6 μL) |
CD15 (20x) MMA (6 μL) |
CD71 (16x) LO1.1 (6 μL) |
| PE |
CD11b (D12) (6 μL) |
123 (SSDCLY107D2) (6 μL) |
CD117 (104D2) (6 μL) |
| PerCP-Cy5.5/PC5.5 |
HLA-DR (L243) (5 μL) |
CD34 (8G12) (5 μL) |
CD33 (16x) (D3HL60.251) (5 μL) |
| PC7 |
CD13 (Immu 103.4) (5 μL) |
CD13 (Immu 103.4) (5 μL) |
CD56 (N901) (5 μL) |
| APC |
CD300e (UP H2) (2.5 μL) |
CD10 (HI10a) (2.5 μL) |
CD34 (581) (2.5 μL) |
| APC-AF750 |
CD64 (2x) (22) (2.5 μL) |
CD16 (30x) (3G8) (5 μL) |
CD38 (HB7) (2.5 μL) |
| PB |
CD4 (16x) (RPA-T4) (5 μL) |
HLA-DR (L243) (1 μL) |
CD7n (8H8.1) (2.5 μL) |
| PO |
CD45 (4x) (HI30) (2.5 μL) |
CD45 (4x) (HI30) (2.5 μL) |
CD45 (4x) (HI30) (2.5 μL) |
|
Intensity of CD11b expression |
| FITC |
- |
CD11b (ICRF44) (6 μL) |
- |
| PE |
CD11b (D12) (6 μL) |
- |
- |
| PerCP-Cy5.5/PC5.5 |
CD33 (16x) (D3HL60.251) (5 μL) |
CD33 (16x) (D3HL60.251) (5 μL) |
- |
| PC7 |
CD13 (Immu 103.4) (5 μL) |
CD13 (Immu 103.4) (5 μL) |
- |
| APC |
CD10 (HI10a) (2.5 μL) |
CD10 (HI10a) (2.5 μL) |
- |
| APC-AF750 |
CD64 (2x) (22) (2.5 μL) |
CD64 (2x) (22) (2.5 μL) |
- |
| PB |
HLA-DR (L243) (1 μL) |
HLA-DR (L243) (1 μL) |
- |
| PO |
CD45 (4x) (HI30) (2.5 μL) |
CD45 (4x) (HI30) (2.5 μL) |
- |
| MDS – myelodysplastic syndromes. On the basis of the upper panel, not only different cell types can be identified but the characteristic MDS-related signs can also be detected. The intensity of CD11b expression was examined with the help of the lower panel. Monocytes and granulocytes were differentiated on the basis of their side scatter character and CD33, CD64, CD45, and HLA-DR expression. |
